癌免疫療法市場：現在の分析と予測2021-2027年

UnivDatos Market Insights (UMI)、は調査レポート「癌免疫療法市場；世界的な機械分析」2021年11月 21日 に発刊しました。レポートは、企業概要 、製品種類、販売量 、市場規模 、メーカ概要 、市場シェア 、などが含まれています。
調査レポートについてーhttps://univdatos.com/report/cancer-immunotherapy-market/

Traditional cancer treatments are still the most practiced and the most standard treatment of medical anti-cancer strategies. While they include surgery, chemotherapy, and radiation therapy, cancer immunotherapy is gaining increasing acceptance and is emerging as a new approach that has recently been revolutionized and just approved. In early 2018, approximately 32 monoclonal antibodies were approved by the FDA or EMA for cancer indications and cancer immunotherapy for medical purposes. The surge in cancer incidence and the growing population of the elderly are expected to boost market growth.

In 2020, an estimated 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) will be diagnosed worldwide and approximately 10 million cancer deaths (9.9 million excluding non-melanoma skin cancer). People) are expected. Breast cancer in women is the most diagnosed cancer, surpassing lung cancer, with an estimated 2.3 million new cases (11.7%), lungs (11.4%), colonic rectum (10.0%), prostate (7.3%), and stomach. I have (5.6%) cancer.

Sample reports over https://univdatos.com/get-a-free-sample-form-php/?product_id=5089

eligibility and reactivity of the AlysonHaslam and VinayPrasad was carried out in 2019 "checkpoint inhibitors immunotherapeutic agents According to a study entitled "Estimating the Percentage of Cancer Patients in the United States," the estimated proportion of cancer patients eligible for checkpoint inhibitors in the United States was 1.54% in 2011, compared to an estimated 26.86 in 2015. %, Increased to 43.63% in 2018. In addition, NSCLC (21.48%), hepatocellular carcinoma (4.95%), and SCLC were the diseases that contributed most to the eligibility calculation (3.79%). In 2016, immunotherapy treatment accounted for 33% of oncology drug spending, even though it accounted for only 9% of FDA-approved oncology drugs. All major oncology drug companies are building strong immunotherapy pipelines to increase M & A and investor interest.

Key players

in the key player market include AbbVie, Amgen, AstraZeneca, bluebird bio, Bristol-Myers Squibb, F. Hoffmann-La Roche, Janssen Biotech, Merck, Novartis, Pfizer and more.

Description of Market Segmentation The

market is the type of treatment (monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, etc.), applications (lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer). , Head and neck cancer, etc.), end users (cancer specialists / research centers, hospitals and clinics), and regions / countries provide insights into segments such as.

The monoclonal antibody segment occupies a major share of the treatment. "

Based on the type of treatment, the market monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapy, immune system modulators, adoptive cell transplantation, has been subdivided, such as cytokines. The monoclonal antibody segment dominated the market with a 37.3% share in 2020

"Among the applications, breast cancer is expected to grow at the largest CAGR during the analysis period"

Further based on the application, the market is lung cancer, breast cancer , Colonic rectal cancer, melanoma, prostate cancer, head and neck cancer, and other cancer applications. By 2020, lung cancer will have the largest market revenue share of 25.5% and is expected to dominate the market during the forecast period.

The report covers North America (US, Canada, other North America), Europe (Germany, UK, Russia, France, Spain, other Europe), Asia Pacific (China, Japan, India, Australia, other APAC), and others. Provides a detailed analysis of major regions and countries, including the world.

North America dominated the market and generated US $ 37.56 billion in revenue in 2020. In the United States, approximately 1.9 million new cancer cases are expected to be diagnosed in 2021. It is estimated that approximately 608,570 Americans will die of cancer in 2021, which is equivalent to approximately 1,670 deaths per day. Cancer is the second leading cause of death in the United States, with only heart disease surpassing it.

Reasons to Buy this Report:

·        This survey includes market size and forecast analysis validated by key certified industry experts

· The        report provides a quick overview of industry-wide performance

· The        report covers a detailed analysis of peers in prominent industries with a major focus on key business finances, product portfolios, expansion strategies, and recent developments.

·        Popular drivers in the industry . , Constraints, Key Trends, and Opportunities Detailed Survey

·        This study comprehensively covers markets across different segments

·        Detailed country-level analytical

 

research reports for the industry- https: // univdatos. com / report / cancer-immunotherapy- market /

 sample report over https://univdatos.com/get-a-free-sample-form-php/?product_id=5089

 

Company Profile

UnivDatos Market Insights (UMI), a subsidiary of Universal Data Solutions, is a fast-growing, dynamic market research company led by a core of dedicated professionals. We provide our clients with sustainable strategies to shape their future business strategies. It provides customized reports, consulting services, and syndicated reports to help aspiring changemakers make wise strategic decisions. Our team of expert analysts critically assess market dynamics, demonstrate competitive intelligence from hard-working sources, and deepen client understanding across a variety of industries.